Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1987-1-30
|
| pubmed:abstractText |
Fifteen patients with advanced malignancy were treated with escalating doses of recombinant beta ser 17 interferon (IFN). Doses ranging from 0.006 to 500 X 10(6) units/m2 were administered according to a dosage escalation scheme by iv push twice weekly (starting 1 week after an initial dose) for a planned minimum of 5 weeks, to be continued as a function of response. Toxic effects were broad in scope but generally low in grade. They included fever, malaise, leukopenia, proteinuria, nausea/vomiting, diarrhea, and mild elevations of serum transaminases and creatinine. In one patient, transient hypotension with bradycardia ensued. Malaise and fever increased somewhat with increasing dose. Doses of up to 500 X 10(6) units/m2 were tolerated without severe toxicity. A maximum tolerated dose was not defined. IFN pharmacokinetics followed a biphasic decay curve, with a distribution phase alpha-half-life of 9 minutes and an elimination phase beta-half-life of 103 minutes. Anti-IFN antibodies by the ELISA technique were present in seven of 15 patients. Presence of antibody did not correlate with toxicity or response. 2',5'-Adenylate synthetase levels were increased 2 and 24 hours after the initial dose, with a trend toward higher increments with higher doses. Minimal anti-tumor responses were seen in two patients with melanoma.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2',5'-Oligoadenylate Synthetase,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon beta 1a,
http://linkedlifedata.com/resource/pubmed/chemical/interferon beta-1b
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0361-5960
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
70
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1365-72
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:3791249-2',5'-Oligoadenylate Synthetase,
pubmed-meshheading:3791249-Adult,
pubmed-meshheading:3791249-Aged,
pubmed-meshheading:3791249-Antibodies,
pubmed-meshheading:3791249-Drug Administration Schedule,
pubmed-meshheading:3791249-Drug Evaluation,
pubmed-meshheading:3791249-Drug-Induced Liver Injury,
pubmed-meshheading:3791249-Female,
pubmed-meshheading:3791249-Hematologic Diseases,
pubmed-meshheading:3791249-Humans,
pubmed-meshheading:3791249-Interferon Type I,
pubmed-meshheading:3791249-Interferon-beta,
pubmed-meshheading:3791249-Kidney Diseases,
pubmed-meshheading:3791249-Kinetics,
pubmed-meshheading:3791249-Lymphocytes,
pubmed-meshheading:3791249-Male,
pubmed-meshheading:3791249-Middle Aged,
pubmed-meshheading:3791249-Nausea,
pubmed-meshheading:3791249-Neoplasms,
pubmed-meshheading:3791249-Recombinant Proteins
|
| pubmed:year |
1986
|
| pubmed:articleTitle |
Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|